Measurement-Based Diagnosis and Treatment for Tardive Dyskinesia

Christoph U. Correll, MD, and Leslie Citrome, MD, MPH

Tardive dyskinesia (TD) is a drug-induced movement disorder associated with agents that block dopamine receptors, particularly antipsychotics. TD commonly involves involuntary movements of the orofacial muscles and the extremities. As a consequence, TD can be associated with serious physical and psychological impairments. This report, based on presentations given by Christoph U. Correll, MD, and Leslie Citrome, MD, MPH, will address how to use measurement-based care to diagnose TD and manage TD treatment.

MEASUREMENT-BASED DIAGNOSIS

Because TD is brought on by the continued use of dopamine receptor blocking agents, such as antipsychotics, many of those at risk are patients with schizophrenia, bipolar disorder, and major depressive disorder. Dr Citrome explained that treating these psychiatric conditions is critical, and many patients may be unable to avoid long-term treatment with these medications despite the risk of TD.

Tardive Dyskinesia Risk Factors and Prevention

Dr Citrome stated that 1 of 4 people who have been exposed to dopamine receptor blocking agents have TD, with a higher percentage among those who have been exposed to first-generation antipsychotics (FGAs). A meta-analysis of prospective, randomized studies showed that second-generation antipsychotics (SGAs) have a significantly lower risk for TD than FGAs. Among individuals who have been exposed only to SGAs, the incidence rate was about 7%. Other risk factors for TD include older age, female sex, presence of a mood disorder, higher cumulative exposure to antipsychotics, emergence of parkinsonism or akathisia, treatment with anticholinergic medications, intermittent antipsychotic treatment, and a history of movement disorders.

Dr Correll noted the importance of managing the risk of TD by educating patients and caregivers about the risks of and alternatives to antipsychotic medication, as well as early signs of TD to watch for if these medications are taken long-term. Clinicians should confirm and document the indication for use of antipsychotics and use conservative maintenance doses; if allowed by the treated condition, the antipsychotic should be stopped after the shortest necessary time. Clinicians should also consider the use of SGAs instead of FGAs, especially for patients at high risk for drug-induced movement disorders, including TD.

Screening for Tardive Dyskinesia

The most recent American Psychiatric Association (APA) guidelines for the treatment of patients with schizophrenia recommend routine assessments for abnormal movements at a set frequency with a formal examination. The use of a structured...
Academic Highlights

It is illegal to post this copyrighted PDF on any website.

Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Financial Disclosure
Dr Correll has received grant/research support and honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan (Viatris), Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; has received grant/research support from Janssen and Takeda; is a member of the speakers/advisory boards for Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedInCell, Merck, Mylan (Viatris), Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; and is a stock shareholder of LB Pharma. Dr Citrome is a consultant for AbbVie, Acadia, Alkermes, Allergan, Avanir, Axsome, BioXcel, Cadent Therapeutics, Eisai, Impel, IntraCellular Therapies, Janssen, Karuna, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Sage, Shire, Sunovion, Takeda, and Teva; is a member of the speakers/advisory boards for AbbVie, Acadia, Alkermes, Allergan, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sage, Shire, Sunovion, Takeda, and Teva; is a stock shareholder of Bristol-Myers-Squibb, Eli Lilly, J&J, Merck, and Pfizer; and has received royalties from Wiley, UpToDate, Springer Healthcare, and Elsevier.

Review Process
The faculty member(s) agreed to provide a balanced and evidence-based presentation and discussed the topic(s) and CME objective(s) during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.

The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.

Dyskinesia” in this series at cmeinstitute.com.

Patient Perspectives

Here, in an interview with a representative of Mental Health America (MHA) in January 2021, a patient described the impact of TD on her work:

“I am fluent in American Sign Language (ASL). I went to school to be an interpreter. I’m completely deaf in one ear. I can’t be an interpreter anymore because the [TD] movements were so severe I couldn’t hold my hands steady long enough to sign in a way where people could typically understand me. I was also certified to be a body piercer. I can’t do that anymore because it’s a safety hazard. So, I just stopped that. What I was able to do and what I was trained and certified to do, I can no longer do.”

Case Practice Question

Discussion of the best response can be found at the end of the activity.

You are seeing a 34-year-old man with schizophrenia for an intake visit, and you notice that he has abnormal involuntary movements. His clinical history indicates that he has been treated with second-generation antipsychotic medication since his diagnosis 12 years ago. He has had parkinsonism and akathisia, for which he received anticholinergic treatment. You decide to perform an Abnormal Involuntary Movement Scale (AIMS) evaluation. Which of the following statements about the AIMS is correct?

a. The AIMS is a diagnostic tool for TD.
b. Given the time required, guidelines do not recommend routine AIMS assessments.
c. The AIMS can assist in measurement-based care and patient education.
d. All of the above

MANAGEMENT APPROACHES

In his presentation, Dr Correll discussed approaches to managing TD. If possible, clinicians may stop the antipsychotic or reduce the dose.11 Increasing the dose could mask TD, but symptoms may re-emerge, leading

It is illegal to post this copyrighted PDF on any website.

For reprints or permissions, contact permissions@psychiatrist.com. © 2021 Copyright Physicians Postgraduate Press, Inc.

J Clin Psychiatry 82:5, September/October 2021

You are prohibited from making this PDF publicly available.
to symptom perpetuation.19 Switching from an FGA to an SGA, or from one SGA antipsychotic to another, are other interventions to consider.11 Dr Correll also highlighted other antidyskinetic agents that may treat TD, all of them with varying degrees of evidence supporting their use, such as vitamin E, vitamin B6, ginkgo biloba, and eicosapentaenoic acid, as well as melatonin, clonazepam, amantadine, donepezil and branched-chain amino acids.11-13 Reserpine, an irreversible vesicular monoamine transporter-2 (VMAT2) inhibitor, has too many adverse effects to be considered, and tetrabenazine, an older reversible VMAT2 inhibitor, also is a potential treatment option, but rigorous trials for TD are missing for tetrabenazine.13 These treatments are not approved by the US Food and Drug Administration (FDA) to treat TD.11

**FDA-Approved Treatments**

Dr Correll focused his presentation on 2 FDA-approved agents to treat TD that are recommended by the American Psychiatric Association for the treatment of moderate to severe or disabling TD.7,14 Both drugs, deutetrabenazine and valbenazine, are reversible VMAT2 inhibitors that reduce the uptake of biogenic amines, particularly dopamine, into presynaptic vesicles.15 Studies have demonstrated that both medications are effective in reducing symptoms of TD acutely and long-term without increased risk of depression or suicidality.14 Dr Correll compared key differentiating features of the 2 treatments (Figure 1).16 Regardless of which treatment is selected, routine monitoring using the AIMS is highly desirable and is essential to providing measurement-based care.7

**Deutetrabenazine.** Deutetrabenazine is closely related chemically to tetrabenazine but is a deuterated drug—selected hydrogen atoms on the tetrabenazine molecule have been replaced with deuterium (a stable, naturally occurring, nonradioactive isotope of hydrogen).17 Deuteration alters the pharmacokinetics of tetrabenazine so that deutetrabenazine has a longer half-life and a lower maximum plasma concentration than tetrabenazine. Increased tolerability and twice-daily dosing (vs 3 doses per day with tetrabenazine) may increase treatment adherence among patients. The initial dose of deutetrabenazine is 6 mg twice per day.14 The dose may be increased by increments of 6 mg/d at weekly intervals with a maximum dose of 24 mg twice a day.

In acute studies, deutetrabenazine was superior to placebo in reducing the severity of dyskinetic movements, measured with the AIMS.14 In an open-label extension study,18 deutetrabenazine showed improvement in both clinician- and patient-rated Global Impression of Change scale scores. At week 6, more than 50% of patients had achieved a “much improved” or “very much improved” outcome. Two-thirds of patients achieved that status by 9 to 12 months, and 3 of 4 patients had done so by the end of 2 years.18

**Valbenazine.** Valbenazine is a highly selective VMAT2 inhibitor. Valbenazine and its principal active metabolite have selective VMAT2 binding,19 limiting off-target receptor binding. Its half-life is 20 hours, which allows for once-daily dosing. The initial dose for valbenazine is 40 mg/d, and the maintenance target dose is 80 mg/d, which can be achieved 1 week after the initial dose.14,19

In acute studies, valbenazine was superior to placebo in reducing the severity of dyskinetic movements, measured with the AIMS.14 An extension study20 showed that at the end of one year, 3 of 4 patients receiving the higher dose of 80 mg/d achieved sustained improvement in both clinician and patient ratings. The lower dose of 40 mg/d led to similar improvement in 60% of patients.

### Drug Interactions

<table>
<thead>
<tr>
<th>Valbenazine</th>
<th>Deutetrabenazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2D6 and CYP3A4 modulators</td>
<td>CYP2D6 modulators</td>
</tr>
</tbody>
</table>

### Contraindications

<table>
<thead>
<tr>
<th>Valbenazine</th>
<th>Deutetrabenazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known hypersensitivity to valbenazine or any components of the product</td>
<td>Hepatic impairment; taking reserpine, monoamine oxidase inhibitors, tetrabenazine, or valbenazine</td>
</tr>
</tbody>
</table>

### Patient Perspectives

In an interview conducted by MHA in January 2021, a patient described the relief from symptoms that she experienced after receiving effective TD medication:

“I’m currently on [an FDA-approved VMAT 2 inhibitor]. It’s taken my movements from a 9 to like a 4 or a 5. [My TD is now] much more tolerable. It’s to where people don’t notice it as much, that they’re not looking at my hands or my legs, focusing in. I don’t have vocal tics anymore unless I’m incredibly stressed out.”

### Patient and Care Partner Communication and Education

According to Dr Correll, clinical experience suggests that most patients with moderate to severe or disabling TD would be willing to take medication to achieve a reduction in their symptoms, particularly if the medication is well tolerated.21 Evidence indicates that the potential benefits of VMAT2 inhibitors for the treatment of TD far outweigh the potential harms.14

---

**Figure 1. Key Features of Deutetrabenazine and Valbenazine**

- **Frequency of administration**
  - Valbenazine: Once daily
  - Deutetrabenazine: Twice daily

- **Titration**
  - Valbenazine: Titrate to target dose of 80 mg/d
  - Deutetrabenazine: Dose to efficacy/tolerability

- **Need for food**
  - Valbenazine: No
  - Deutetrabenazine: Yes

- **Drug interactions**
  - Valbenazine: CYP2D6 and CYP3A4 modulators
  - Deutetrabenazine: CYP2D6 modulators

- **Contraindications**
  - Valbenazine: Known hypersensitivity to valbenazine or any components of the product
  - Deutetrabenazine: Hepatic impairment; taking reserpine, monoamine oxidase inhibitors, tetrabenazine, or valbenazine

---

Reprinted with permission from Citrome and Saklad.16
Academic Highlights

Dr. Correll concluded by emphasizing good communication with patients and caregivers about risk factors for TD, signs of TD, and treatment options. It is important for clinicians to inquire about and address TD symptoms with each patient and jointly develop treatment goals. The AIMS examination can provide a backdrop for these discussions. Dr. Correll offered these example questions: “What is it that you would want the most for yourself (or your loved one) from an effective treatment? What are your goals? How can we measure the outcome to see whether we reach your goals?” Dr. Correll also emphasized the importance of setting expectations with patients about medications and their side effects.

Clinical Points

- Differentiate between TD and other drug-induced movement disorders, particularly drug-induced Parkinsonism.
- Use the AIMS examination to screen for and routinely monitor TD, especially when providing treatments intended to decrease the symptoms of TD.
- For patients who have moderate to severe or disabling TD, the APA recommends treatment with FDA-approved VMAT2 inhibitors deutetrabenazine and valbenzine.
- Discuss treatment goals and expectations with patients and care partners.

Discussion of Case Practice Question

Preferred response is c. The AIMS can assist in measurement-based care and patient education. The AIMS is not a diagnostic tool, as other medical reasons for the dyskinetic movements need to be ruled out first. This patient is at risk for TD because of long-term antipsychotic treatment, even though he took second-generation medications. Extrapyramidal side effects such as parkinsonism and akathisia are relevant risk factors for TD, and anticholinergic medications for them do not reduce, but potentially further increase, TD risk. The APA guidelines recommend regular use of structured assessments such as the AIMS, in addition to clinical assessments at each visit, to facilitate measurement-based care. The AIMS can be helpful in assisting in the quantification of the dyskinetic movements, which can be useful when documenting a baseline prior to treatment and can aid patient education.

Published online: August 31, 2021.

Disclosure of off-label usage: The chair has determined that, to the best of his knowledge, vitamin E, vitamin B6, ginkgo biloba, icosaepentaenoic acid, melatonin, clonazepam, amantadine, donepezil, branched-chain amino acids, reserpine, and tetrabenazine are not approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.

REFERENCES


To obtain credit, go to PSYCHIATRIST.COM to complete the Posttest and Evaluation.

1. For which type(s) of tardive dyskinesia (TD) does the American Psychiatric Association recommend treatment with an approved vesicular monoamine transporter-2 (VMAT2) inhibitor?
   a. Emerging symptoms and signs of TD
   b. Mild forms of TD
   c. Moderate to severe or disabling TD
   d. All of the above

2. You are treating a 45-year-old woman with schizophrenia who has developed moderate TD after 7 years of antipsychotic treatment. When you initiate treatment for TD, which of the following pharmacokinetically driven actions is most appropriate?
   a. Prescribe either deutetrabenazine or valbenzine twice daily with food
   b. Prescribe either deutetrabenazine or valbenzine once daily with food
   c. Prescribe either deutetrabenazine or valbenzine once daily without relationship to food
   d. Prescribe deutetrabenazine twice daily with or without relationship to food

For reprints or permissions, contact permissions@psychiatrist.com. © 2021 Copyright Physicians Postgraduate Press, Inc.